Safety of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-Adjuvanted Cell Culture-derived Influenza Vaccine in Healthy Subjects ≥18 Years of Age

Category Primary study
ConferenceAnnual Meeting of the Infectious Diseases Society of America, ID Week 2025
Year 2026
This article has no abstract
Epistemonikos ID: 6c34e22d1ae596616675a0f4ecf53a3f87ae8c87
First added on: Mar 21, 2026